| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 10/21/2004 | WO2004089344A1 Process for producing tablet |
| 10/21/2004 | WO2004089282A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 10/21/2004 | WO2004052389A3 Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system |
| 10/21/2004 | WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 10/21/2004 | WO2003097163A3 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions |
| 10/21/2004 | WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 10/21/2004 | WO2003004025A8 High purity amlodipine benzenesulfonate and a process for its preparation |
| 10/21/2004 | WO2003000014A3 Spherical protein particles and methods of making and using them |
| 10/21/2004 | WO1995018619A9 Bicyclic fibrinogen antagonists |
| 10/21/2004 | US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS) |
| 10/21/2004 | US20040210269 Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the BBB and cerbral blood flow |
| 10/21/2004 | US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders |
| 10/21/2004 | US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 10/21/2004 | US20040209957 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke |
| 10/21/2004 | US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 10/21/2004 | US20040209936 Compounds that modulate PPAR activity and methods of preparation |
| 10/21/2004 | US20040209935 Pyrazole-derived kinase inhibitors and uses thereof |
| 10/21/2004 | US20040209922 Pyridine matrix metalloproteinase inhibitors |
| 10/21/2004 | US20040209920 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
| 10/21/2004 | US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 10/21/2004 | US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments |
| 10/21/2004 | US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors. |
| 10/21/2004 | US20040209899 A2B adenosine receptor antagonists |
| 10/21/2004 | US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine |
| 10/21/2004 | US20040209885 Combination therapy for the treatment of heart failure |
| 10/21/2004 | US20040209883 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209872 Calcium channel blockers comprising two benzhydril moieties |
| 10/21/2004 | US20040209870 contain 5-HT ligands used to treat central nervous system disorders |
| 10/21/2004 | US20040209868 Substituted indoles |
| 10/21/2004 | US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209817 Methods and compositions for the treatment of peripheral artery disease |
| 10/21/2004 | US20040209812 Use of erythropoietin in stroke recovery |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209802 Administering erythropoietin or derivative to treat diabetes |
| 10/21/2004 | US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites |
| 10/21/2004 | US20040209288 Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208857 Producing a donor-specific immunotolerance against transplanted tissue by administering embryonic stem cell-like cell lines (ECL) obtained from blastocysts and are transfected with genetic material of the donor, which codes for the major histocompatibility complex (MHC) haplotypes |
| 10/21/2004 | US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents |
| 10/21/2004 | US20040208844 Products and drug delivery vehicles |
| 10/21/2004 | CA2523186A1 Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby |
| 10/21/2004 | CA2521875A1 Calcium channel blockers comprising two benzhydril moieties |
| 10/21/2004 | CA2521433A1 Piperidine derivatives as renin |
| 10/21/2004 | CA2521400A1 Piperazine derivative renin inhibitors |
| 10/21/2004 | CA2521303A1 The use of pde4d in the screening for medicaments against atherosclerosis |
| 10/21/2004 | CA2520347A1 Prostaglandin compositions and their use for the treatment of vasospasm |
| 10/21/2004 | CA2519882A1 Novel crystals of fluorobenzamide derivative |
| 10/21/2004 | CA2517336A1 Purin-6-one-derivatives |
| 10/20/2004 | EP1469077A1 Cell-specific expression/replication vector |
| 10/20/2004 | EP1468989A2 Compounds and methods for the inhibition of the expression of VCAM-1 |
| 10/20/2004 | EP1468691A1 Use of bisphosphonates in the treatment of vascular restenosis |
| 10/20/2004 | EP1468682A1 Therapeutic combinations comprising amlodipine and atorvastatin |
| 10/20/2004 | EP1468680A2 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| 10/20/2004 | EP1468097A2 METHODS OF GENERATING MULTISPECIFIC, MULTIVALENT AGENTS FROM V sb H /sb AND V sb L /sb DOMAINS |
| 10/20/2004 | EP1468091A2 Transmembrane protein |
| 10/20/2004 | EP1468020A2 Multimers of receptor-binding ligands |
| 10/20/2004 | EP1468019A2 Secreted protein |
| 10/20/2004 | EP1468018A2 Leptin proteins |
| 10/20/2004 | EP1468010A1 Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds |
| 10/20/2004 | EP1468003A2 Phosphinic pseudo-peptide derivatives |
| 10/20/2004 | EP1467999A1 Oxothieno[3,2-b]pyridinecarboxamides as antiviral agents |
| 10/20/2004 | EP1467998A1 Tetracyclic heterocompounds as estrogen receptor modulators |
| 10/20/2004 | EP1467997A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
| 10/20/2004 | EP1467995A2 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/20/2004 | EP1467982A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
| 10/20/2004 | EP1467979A2 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION |
| 10/20/2004 | EP1467976A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 10/20/2004 | EP1467975A1 Substituted alkyl uracils and the use thereof |
| 10/20/2004 | EP1467972A1 Indazole compounds useful as protein kinase inhibitors |
| 10/20/2004 | EP1467968A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467965A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467801A1 Method of prophylaxis against large myocardial infarctions |
| 10/20/2004 | EP1467760A2 Systems and methods for photodynamic therapy |
| 10/20/2004 | EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS |
| 10/20/2004 | EP1467750A1 Orodispersible pharmaceutical composition comprising perindopril |
| 10/20/2004 | EP1467749A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 10/20/2004 | EP1467741A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 10/20/2004 | EP1467740A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 10/20/2004 | EP1467739A2 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators |
| 10/20/2004 | EP1467735A2 Polymorphs of clopidogrel hydrogensulfate |
| 10/20/2004 | EP1467733A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 10/20/2004 | EP1467732A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 10/20/2004 | EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 10/20/2004 | EP1467728A1 Pharmaceutical compositions comprising valsartan and nep inhibitors |
| 10/20/2004 | EP1467727A1 1,3-disubstituted and 1,3,3,-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 10/20/2004 | EP1467721A2 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 10/20/2004 | EP1467714A1 Drug mixture with enhanced dissolution rate |
| 10/20/2004 | EP1368327B1 Benzo thiadiazine matrix metalloproteinase inhibitors |
| 10/20/2004 | EP1263725B1 Novel compounds |
| 10/20/2004 | EP1261588B1 IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS |
| 10/20/2004 | EP1246619B1 Urotensin-ii receptor antagonists |
| 10/20/2004 | EP1232252A4 Reversibly inactivated acidified plasmin |
| 10/20/2004 | EP1230236B1 Compound with growth hormone releasing properties |
| 10/20/2004 | EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 10/20/2004 | EP1206268B1 Novel compositions for controlled release of a biologically active agent, and the preparation thereof |
| 10/20/2004 | EP1198477B1 Prolactin-releasing peptide and use in treating pain |
| 10/20/2004 | EP1171143B1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |